SecBot SecBot
8-K ·Filed Aug 4, 2026

ZEOX

Zeo ScientifiX, Inc.
NEUTRAL
Impact 2/10
Horizonmonths Processed2mo ago SEC0001829126-26-008299
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

This is a routine marketing event with no financial data — no immediate trading catalyst. Monitor for future registration numbers or follow-on filings that might indicate revenue generation from the event.

DirectionNeutral
Confidencehigh
Horizonmonths
Latest settled — T+20d
ZEOX ▼ -14.16% at T+20d
NEUTRAL call -14.16% · α vs SPY -12.93% · entry $1.40 → $1.20
Next anchor: T+60d in 18h
Latest observation: T+57 +65.74% FF3 residual α
Entry = T+0 close
Aug 4, 2026
via day close
T+1d
+3.15%
call +3.15% · α +3.35%
$1.44
settled 3mo ago
T+5d
+8.73%
call +8.73% · α +8.83%
$1.52
settled 3mo ago
T+20d
-14.16%
call -14.16% · α -12.93%
$1.20
settled 8w ago
T+60d
Pending
in 18h

Price Chart

Loading chart...

Executive Summary

Zeo ScientifiX announced the launch of ZEO Xperience, a three-day immersive educational conference for healthcare professionals focused on regenerative biologics, to be held October 23-25, 2026. This is a marketing and physician education event with no financial terms disclosed, no revenue implications, and no material impact on the company's clinical-stage operations or financial position.

Key Facts

  • ZEO launched ZEO Xperience, a three-day immersive educational experience for healthcare professionals.
  • The event will take place October 23-25, 2026 at Pier Sixty-Six Resort in Fort Lauderdale, Florida.
  • The conference covers regenerative biologics education, clinical training, practice growth strategies, and a biohacking experience.
  • Attendance is intentionally limited to create an interactive environment.
  • No financial terms, revenue projections, or material business developments were disclosed.

Financial Impact

No financial impact disclosed; event is a marketing/education initiative with no stated revenue or cost figures.

Risk Factors

  • No financial details provided; event costs and attendance revenue are unknown.
  • As a clinical-stage biopharma company, ZEOX has no approved products and this event does not change its fundamental risk profile.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001829126-26-008299
Document: zeoscientifix_ex99-1.htm0001829126-26-008299
Document: 0001829126-26-008299-index-headers.html0001829126-26-008299
Document: 0001829126-26-008299-index.html0001829126-26-008299
Document: 0001829126-26-008299.txt0001829126-26-008299
14 reports for ZEOX
Performance horizon
67% Hit rate @ T+20 2 of 3 directional calls Went positive at some point 3 of 3 best @ T+20▲ +13.87%Apr 9, 2026
Filters
Rows
Reports for ZEOX — sortable, filterable
TypeNow
Oct 26, 2026
1d ago
8-K
NEUTRAL ★ 5/10
$1.48awaiting T+20—$1.18 (−20.27%)
Sep 15, 2026
6w ago
8-K
NEUTRAL ★ 2/10
$1.36 $1.15▼ −15.44%▼ −18.42%$1.18 (−13.24%)
Sep 1, 2026
8w ago
8-K
NEUTRAL ★ 2/10
$1.20 $1.39▲ +15.83%▲ +14.65%$1.18 (−1.67%)
Aug 4, 2026
12w ago
8-K
NEUTRAL ★ 2/10
$1.40 $1.20▼ −14.16%▼ −12.93%$1.18 (−15.59%)
Jul 21, 2026
14w ago
8-K
NEUTRAL ★ 2/10
$1.69 $1.55▼ −8.28%▼ −10.85%$1.18 (−30.18%)
Jul 8, 2026
15w ago
8-K
BULLISH ★ 5/10
$1.80 $1.40▼ −22.33%▼ −25.61%$1.18 (−34.44%)
Jul 1, 2026
16w ago
8-K
NEUTRAL ★ 1/10
$1.77 $1.65▼ −6.78%▼ −4.59%$1.18 (−33.33%)
Jun 16, 2026
19w ago
8-K
NEUTRAL ★ 2/10
$1.72 $1.94▲ +12.79%▲ +11.93%$1.18 (−31.40%)
Jun 9, 2026
20w ago
8-K
NEUTRAL ★ 2/10
$1.67 $1.80▲ +7.78%▲ +6.39%$1.18 (−29.34%)
May 27, 2026
21w ago
8-K
NEUTRAL ★ 2/10
$1.85 $1.70▼ −8.11%▼ −6.21%$1.18 (−36.22%)
Showing 10 of 14

US Market Status

Market Open — Closes in 1h 50m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 4, 2026